Search

LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).

Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data

LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Key Updates

Key Updates

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Key updates